Download full-text PDF |
Source |
---|
J Public Health Policy
March 2020
Department of Bio-Engineering, Imperial College London, Kensington, London, SW7 2AZ, UK.
We undertook this study in light of an uncontrolled rise of melanoma incidence and mortality rates in the United Kingdom (UK). We aim to assess the effectiveness of prevention and early melanoma diagnosis in the UK's National Health Service (NHS) in comparison to the Australian system that has limited the melanoma rise. We compare the prevention campaigns against skin cancer and the stage at which melanoma is diagnosed.
View Article and Find Full Text PDFNPJ Prim Care Respir Med
August 2019
Imperial College London, London, UK.
The Salford Lung Study in Asthma (SLS Asthma) was a multicentre, randomised, controlled, open-label trial that assessed initiating once-daily, single-inhaler fluticasone furoate/vilanterol (FF/VI) 100 μg/25 μg or 200 μg/25 μg versus continuing usual care. A subgroup (n = 400) from SLS Asthma was enrolled in this exploratory, interview-based follow-up study. Quantitative and qualitative data were collected via questionnaires.
View Article and Find Full Text PDFThe NHS for England now has future plans for the next 10 years: but the documents say little about the problems -likely to be encountered. The paper outlines two main -problems - the poor record for expanding services out of -hospital and the crowding out effect of hospital spending - and it sets out some directions for future action to make sure that development continues in the out-of-hospital space.
View Article and Find Full Text PDFNPJ Prim Care Respir Med
May 2019
Imperial College London, London, UK.
The Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) was a 12-month, Phase III, open-label, randomised study comparing the effectiveness and safety of initiating once-daily fluticasone furoate 100 µg/vilanterol 25 µg (FF/VI) with continuing usual care (UC). Follow-up interviews were conducted among a subset of 400 patients who completed SLS COPD to further understand patients' experiences with treatment outcomes and the impact of COPD, and potential risk factors associated with higher rates of exacerbations during SLS COPD. Another objective was to explore how such patient-centred outcomes differed by randomised treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!